Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
OCULAR THERAPEUTIX, INC reported the full year ended December 31, 2023 results: revenue $58.4 million.
- Period
- the full year ended December 31, 2023
- Revenue
- $58.4 million
- Result
- reported results
Exact text from the filing
Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
OCULAR THERAPEUTIX, INC reported the fourth quarter 2023 results: revenue $14.8 million, net income $(29.2) million, EPS $(0.35) per share on both a basic and diluted basis.
- Period
- the fourth quarter 2023
- Revenue
- $14.8 million
- Net income
- $(29.2) million
- EPS
- $(0.35) per share on both a basic and diluted basis
- Result
- reported results
Exact text from the filing
Total net revenue was $14.8 million for the fourth quarter of 2023, a 5.0% increase over total net revenue of $14.1 million in the comparable period in 2022, driven by DEXTENZA sales. Total net revenue for the full year 2023 was $58.4 million versus $51.5 million in 2022, an increase of 13.4%. Research and development expenses for the fourth quarter of 2023 were $16.2 million versus $13.5 million for the comparable period in 2022, driven primarily by an increase in overall clinical and regulatory expenses associated with product development programs. Overall R&D expenses for the full year increased $7.6 million to $61.1 million from $53.5 million in 2022, reflecting the timing and conduct of our clinical trials. Selling and marketing expenses were $9.2 million in the fourth quarter of 2023, as compared to $10.5 million for the comparable quarter of 2022, primarily reflecting a reduction in personnel costs driven by lower expense for stock-based compensation and other items. Overall, se
View on SEC.gov